FUTURE OF HEALTHCARE

Modivcare Announces Acquisition of Guardian Medical Monitoring

Modivcare Inc. | May 19, 2022

Modivcare Announces

Modivcare Inc. a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes,  announced the Company’s Remote Patient Monitoring Segment has acquired Guardian Medical Monitoring, LLC from its parent company, Guardian Alarm.

Guardian Medical Monitoring is a leading provider of remote patient monitoring solutions to Managed Care Organizations and state Medicaid payors including Personal Emergency Response Systems and medication management. GMM’s RPM platform currently monitors approximately 50,000 aging and chronically ill patients on behalf of their respective payors.

Remote patient monitoring is essential to Modivcare’s mission to connect patients to care through our integrated supportive care platform. Our comprehensive remote patient monitoring offering allows patients to safely age in their homes with technology-enabled connectivity to care which increases patient engagement and reduces costs. We are excited to accelerate the growth of Modivcare’s RPM Segment with the acquisition of GMM, and we are excited to welcome the GMM team to Modivcare.”

Daniel E. Greenleaf, Modivcare’s President and Chief Executive Officer

Jason Anderson, President, Modivcare Home added, “Guardian Medical Monitoring is a complementary acquisition for Modivcare’s RPM Segment, strengthening our customer relationships and expanding our service footprint across key states. Additionally, this acquisition provides an opportunity to expand our E3 engagement platform across a larger base of members and payors. Modivcare’s E3 platform helps our partners reduce gaps in care and address social determinants of health by engaging, educating, and empowering members using our proprietary platform.”

About Modivcare

Modivcare Inc. is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation, personal care and remote patient monitoring. 

Spotlight

Life sciences companies are facing increasing pressure to provide new products to market faster than ever before while adhering to the growing number of safety and regulatory needs. Pfizer, one of the world's largest pharmaceutical companies, is transforming its business with an application network that enables the scale and spe

Spotlight

Life sciences companies are facing increasing pressure to provide new products to market faster than ever before while adhering to the growing number of safety and regulatory needs. Pfizer, one of the world's largest pharmaceutical companies, is transforming its business with an application network that enables the scale and spe

Related News

HEALTH TECHNOLOGY

Redox and Intelligent Medical Objects Partnering to Augment Healthcare Data

Redox Inc. | October 18, 2022

Redox, the company setting the stage for composable healthcare, has partnered with Intelligent Medical Objects, a healthcare data enablement company to standardize clinical data from diverse systems into consistent, structured, clinically validated terminology including comprehensive mapping to major global coding systems. Now healthcare companies can spend more time building improved patient and clinician experiences by eliminating the lengthy and taxing process of combining multiple point solutions. This announcement comes directly after last week's launch of API Actions, a modular way for healthcare companies to build out their ideal workflows. This present partnership between IMO and Redox benefits any healthcare company that receives clinical problem or diagnosis data from multiple organizations. As a result, these are further able to enrich healthcare data using consistent terminology across all data standards, formats, and workflows with a single Redox API. "Redox is dedicated to making sure that healthcare data can empower builders to create new experiences for patients and providers. We want to be clear that composable healthcare is a practice of bringing together the best technologies to produce the best solutions, and we're glad to be doing so with IMO." Redox CEO Luke Bonney "Clinical patient data is a powerful resource in healthcare. IMO partnering with Redox will accelerate the ability for healthcare companies to leverage that data to create better outcomes for doctors and patients," said IMO CEO Ann Barnes. Redox will leverage IMO's technology to standardize healthcare data for its customers. Using IMO Precision Normalize will allow Redox to accelerate data normalization for its hospital and software vendor clients. This lets healthcare technology companies spend more time building powerful solutions by eliminating the lengthy and costly process of cleaning and standardizing messy clinical data. SNOMED® is a registered trademark of International Health Terminology Standards Development Organisation About Redox Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before. About IMO Intelligent Medical Objects is a healthcare data enablement company. From clinical documentation at the point of care to complex approaches to population health management, IMO ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem. For almost three decades, IMO's footprint in EHRs—across more than 4,500 US hospitals—powers our expert ability to capture and preserve clinical intent wherever and however data is used. Our primary clients span individual doctors and physician groups, hospitals and clinics, large integrated delivery networks, inpatient ORs and surgical centers, global electronic health record providers, health information exchanges, clinical data registries, payers, life sciences companies, and healthcare analytics vendors.

Read More

HEALTH TECHNOLOGY

Eleos Health and The Echo Group Announce Strategic Partnership to Advance the use of Augmented Intelligence in Behavioral Health

Eleos Health and Echo Group | September 16, 2022

Eleos Health, the leader in CareOps Automation for behavioral health, and The Echo Group, the only provider of visual electronic health record technology, announced that Eleos Health's augmented intelligence will be directly embedded into the EchoVantage web-based clinical, billing, and administrative EHR application to serve the needs of behavioral healthcare clinicians. Eleos Health and EchoVantage will act in synergy to reduce administrative burdens on clinicians. Medical professionals face an increasing number of administrative tasks, spending an average of 20% of their total working hours on administration. In general, notes for each session take about 15 minutes to complete, with the average full-time clinician doing so for 40 sessions per week. Eleos will turn behavioral health conversations into documentation and session intelligence, plugging directly into EchoVantage's visual health record (VHR). The VHR provides clinicians with a client's case across a timeline, with visual indicators providing an understandable and actionable graphical format. Clinicians using Eleos reduce time spent on documentation by over 30%. This increase in efficient and accurate documentation also equips supervisors with unprecedented visibility into staff activity, caseloads and performance to make it easier for providers to meet organizational standards for documentation, while empowering providers to improve training with structured, objective feedback on their sessions. "Eleos Health is excited to add The Echo Group to our growing base of strategic partners who are dedicated to advancing the standard of care in behavioral health. By enhancing the EchoVantage EHR with our augmented intelligence capabilities, we will give clinicians the ability to spend less time on administrative tasks and more time impacting the lives of those managing behavioral health conditions," Alon Joffe, CEO and Co-Founder, Eleos Health EchoVantage ensures that all aspects of the clinical chart are fully integrated and organized, along with the timeline, in relation to each other. This lends true clinical understanding to precipitating events and treatment activities. "The expansion of our national offering to include Eleos Health as an embedded platform for all of our customers is a huge benefit for clinicians and their patients," said Allan Normandin, Chief Executive Officer, The Echo Group. "The Echo Group is focused on finding ways to empower our customers to be more clinically effective and financially strong. Working with Eleos Health is another step in achieving that goal by reducing the barrier of administrative tasks in the continuum of care." This partnership puts overburdened clinicians back into the office working with clients instead of spending their time typing notes into their EHR. Beyond simplifying documentation, , this partnership will enable clinicians to quickly understand the themes in their meetings, such as suicidal thoughts or cognitive-behavioral therapy techniques, and pursue the best evidence-based practices. Eleos Health's proprietary voice-based Natural Language Understanding (NLU) technology accurately identifies evidence-based techniques, as well as interprets the meaning of behavioral health conversations, giving clinicians objective feedback they can use with patients to identify recurring themes, issues and needs. Eleos Health will be available to all of The Echo Group's clients as an add-on, with GRAND Mental Health, in Northeastern and North Central Oklahoma, being the first center to leverage the power of both systems to help give its care providers more time for patients. The Echo Group's partners are located throughout the U.S. and range in size, from small community behavioral health agencies to comprehensive enterprise-wide organizations. "The ability to reduce administrative burdens for clinicians while also increasing visibility around the quality of care is invaluable in giving our staff the freedom and tools they need to focus on our mission of improving quality of life for consumers," said Josh Cantwell, COO, GRAND Mental Health. "The Eleos Health and Echo Group partnership will meaningfully ability to support clinicians and serve our communities." About Eleos Health Founded in 2020, Eleos Health turns behavioral health conversations into documentation and intelligence that drives better care. Using proprietary, voice-based Natural Language Understanding (NLU) technology built by clinical experts to accurately interpret, analyze and document behavioral health conversations, Eleos reduces the operational burden on providers while unlocking objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training while gaining unprecedented visibility into staff activity, caseloads and performance as well as population health. Eleos is the only technology of its kind that embeds seamlessly into electronic health records (EHRs), telehealth tools and existing provider workflows. With Eleos CareOps Automation, behavioral health providers are setting a new standard for care. About The Echo Group The Echo Group, privately held since 1980, revolutionized electronic health records in the behavioral health industry with EchoVantage, the only EHR featuring a visual continuum of care timeline. EchoVantage is a core, integrated EHR platform with a complete suite of tools designed to conform to your workflow, meet compliance requirements, and increase productivity, enabling you to spend more time putting your clients. The Echo Group is located in Conway, New Hampshire, with an additional office in California. Echo has more than 80 employees dedicated to making the best behavioral health technology in the industry.

Read More

HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution. The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections. The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs. "We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias." Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022 At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study. "These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy." The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

Read More